These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 32338803)

  • 1. Long-term hepatitis B surface antigen (HBsAg) kinetics during entecavir treatment in Korean patients-Functional cure unlikely.
    Cho JY; Sohn W; Paik YH; Gwak GY; Choi MS; Lee JH; Koh KC; Paik SW; Park CG
    J Viral Hepat; 2020 Sep; 27(9):951-954. PubMed ID: 32338803
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term outcome of entecavir treatment of nucleos(t)ide analogue-naïve chronic hepatitis B patients in Japan.
    Suzuki F; Hosaka T; Suzuki Y; Sezaki H; Akuta N; Fujiyama S; Kawamura Y; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kobayashi M; Mineta R; Suzuki Y; Kumada H
    J Gastroenterol; 2019 Feb; 54(2):182-193. PubMed ID: 30136216
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ALT to qHBsAg ratio predicts long-term HBsAg seroclearance after entecavir cessation in Chinese patients with chronic hepatitis B.
    Leung RH; Hui RW; Mak LY; Mao X; Liu KS; Wong DK; Fung J; Seto WK; Yuen MF
    J Hepatol; 2024 Aug; 81(2):218-226. PubMed ID: 38527527
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical utility of hepatitis B surface antigen kinetics in treatment-naïve chronic hepatitis B patients during long-term entecavir therapy.
    Lin TC; Chiu YC; Chiu HC; Liu WC; Cheng PN; Chen CY; Chang TT; Wu IC
    World J Gastroenterol; 2018 Feb; 24(6):725-736. PubMed ID: 29456411
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trajectories of serum hepatitis B surface antigen kinetics in patients with chronic hepatitis B receiving long-term nucleos(t)ide analogue therapy.
    Hsu WF; Chen CF; Lai HC; Su WP; Lin CH; Chuang PH; Chen SH; Chen CH; Wang HW; Huang GT; Peng CY
    Liver Int; 2018 Apr; 38(4):627-635. PubMed ID: 28857411
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Baseline hepatitis B surface antigen quantitation can predict virologic response in entecavir-treated chronic hepatitis B patients.
    Wang CC; Tseng TC; Wang PC; Lin HH; Kao JH
    J Formos Med Assoc; 2014 Nov; 113(11):786-93. PubMed ID: 23911291
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changes of HBsAg and interferon-inducible protein 10 serum levels in naive HBeAg-negative chronic hepatitis B patients under 4-year entecavir therapy.
    Papatheodoridis G; Goulis J; Manolakopoulos S; Margariti A; Exarchos X; Kokkonis G; Hadziyiannis E; Papaioannou C; Manesis E; Pectasides D; Akriviadis E
    J Hepatol; 2014 Jan; 60(1):62-8. PubMed ID: 24012614
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantitative hepatitis B surface antigen analysis in hepatitis B e antigen-positive nucleoside-naive patients treated with entecavir.
    Gish RG; Chang TT; Lai CL; de Man RA; Gadano A; Llamoso C; Tang H
    Antivir Ther; 2013; 18(5):691-8. PubMed ID: 23510982
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Different HBsAg decline after 3 years of therapy with entecavir in patients affected by chronic hepatitis B HBeAg-negative and genotype A, D and E.
    Boglione L; Cardellino CS; De Nicolò A; Cariti G; Di Perri G; D'Avolio A
    J Med Virol; 2014 Nov; 86(11):1845-50. PubMed ID: 25131947
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes of HBsAg and HBV DNA levels in Chinese chronic hepatitis B patients after 5 years of entecavir treatment.
    Seto WK; Lam YF; Fung J; Wong DK; Huang FY; Hung IF; Lai CL; Yuen MF
    J Gastroenterol Hepatol; 2014 May; 29(5):1028-34. PubMed ID: 24325451
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantification of HBsAg in nucleos(t)ide-naïve patients treated for chronic hepatitis B with entecavir with or without tenofovir in the BE-LOW study.
    Zoulim F; Carosi G; Greenbloom S; Mazur W; Nguyen T; Jeffers L; Brunetto M; Yu S; Llamoso C
    J Hepatol; 2015 Jan; 62(1):56-63. PubMed ID: 25176615
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sequential combination therapy with pegylated interferon leads to loss of hepatitis B surface antigen and hepatitis B e antigen (HBeAg) seroconversion in HBeAg-positive chronic hepatitis B patients receiving long-term entecavir treatment.
    Li GJ; Yu YQ; Chen SL; Fan P; Shao LY; Chen JZ; Li CS; Yi B; Chen WC; Xie SY; Mao XN; Zou HH; Zhang WH
    Antimicrob Agents Chemother; 2015 Jul; 59(7):4121-8. PubMed ID: 25941216
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cumulative incidence of hepatocellular carcinoma and hepatitis B surface antigen Seroclearance after Nucleos(t) ide analogue-induced hepatitis B e antigen Seroclearance.
    Lee HW; Lee JI; Kim S; Kim S; Chang HY; Lee KS
    BMC Gastroenterol; 2020 Apr; 20(1):113. PubMed ID: 32305059
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Kinetics and prediction of HBsAg loss during therapy with analogues in patients affected by chronic hepatitis B HBeAg negative and genotype D.
    Boglione L; D'Avolio A; Cariti G; Gregori G; Burdino E; Baietto L; Cusato J; Ghisetti V; De Rosa FG; Di Perri G
    Liver Int; 2013 Apr; 33(4):580-5. PubMed ID: 23311449
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability.
    Kim GA; Lim YS; An J; Lee D; Shim JH; Kim KM; Lee HC; Chung YH; Lee YS; Suh DJ
    Gut; 2014 Aug; 63(8):1325-32. PubMed ID: 24162593
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early hepatitis B surface antigen decline predicts treatment response to entecavir in patients with chronic hepatitis B.
    Peng CY; Lai HC; Su WP; Lin CH; Chuang PH; Chen SH; Chen CH
    Sci Rep; 2017 Feb; 7():42879. PubMed ID: 28220833
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term entecavir therapy results in falls in serum hepatitis B surface antigen levels and seroclearance in nucleos(t)ide-naïve chronic hepatitis B patients.
    Hara T; Suzuki F; Kawamura Y; Sezaki H; Hosaka T; Akuta N; Kobayashi M; Suzuki Y; Saitoh S; Arase Y; Ikeda K; Kobayashi M; Watahiki S; Mineta R; Kumada H
    J Viral Hepat; 2014 Nov; 21(11):802-8. PubMed ID: 25274427
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantitative hepatitis B surface antigen levels in patients with chronic hepatitis B after 2 years of entecavir treatment.
    Fung J; Lai CL; Young J; Wong DK; Yuen J; Seto WK; Yuen MF
    Am J Gastroenterol; 2011 Oct; 106(10):1766-73. PubMed ID: 21826112
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association Between Level of Hepatitis B Surface Antigen and Relapse After Entecavir Therapy for Chronic Hepatitis B Virus Infection.
    Chen CH; Hung CH; Hu TH; Wang JH; Lu SN; Su PF; Lee CM
    Clin Gastroenterol Hepatol; 2015 Nov; 13(11):1984-92.e1. PubMed ID: 26073492
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Off-therapy precipitous HBsAg decline predicts HBsAg loss after finite entecavir therapy in HBeAg-negative patients.
    Jeng WJ; Chang ML; Liaw YF
    J Viral Hepat; 2019 Aug; 26(8):1019-1026. PubMed ID: 31009126
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.